BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34752846)

  • 1. Enzalutamide-induced and PTH1R-mediated TGFBR2 degradation in osteoblasts confers resistance in prostate cancer bone metastases.
    Su S; Cao J; Meng X; Liu R; Vander Ark A; Woodford E; Zhang R; Stiver I; Zhang X; Madaj ZB; Bowman MJ; Wu Y; Xu HE; Chen B; Yu H; Li X
    Cancer Lett; 2022 Jan; 525():170-178. PubMed ID: 34752846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Establishment of enzalutamide-resistant human prostate cancer cell lines and screening of lncRNA and mRNA expression profiles].
    Guan H; Ling ZX; Fang F; Mao LK; You ZH; Wang C; Chen SQ; Xu B; Chen M
    Zhonghua Nan Ke Xue; 2018 Feb; 24(2):116-121. PubMed ID: 30156069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of TGF-β signaling in osteoblasts increases basic-FGF and promotes prostate cancer bone metastasis.
    Meng X; Vander Ark A; Daft P; Woodford E; Wang J; Madaj Z; Li X
    Cancer Lett; 2018 Apr; 418():109-118. PubMed ID: 29337106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.
    Liu C; Armstrong CM; Lou W; Lombard AP; Cucchiara V; Gu X; Yang JC; Nadiminty N; Pan CX; Evans CP; Gao AC
    Mol Cancer Ther; 2017 Aug; 16(8):1521-1530. PubMed ID: 28500234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Genes Required for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells
    Kohrt SE; Awadallah WN; Phillips RA; Case TC; Jin R; Nanda JS; Yu X; Clark PE; Yi Y; Matusik RJ; Anderson PD; Grabowska MM
    Mol Cancer Ther; 2021 Feb; 20(2):398-409. PubMed ID: 33298586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flightless I Homolog Reverses Enzalutamide Resistance through PD-L1-Mediated Immune Evasion in Prostate Cancer.
    Ruan H; Bao L; Tao Z; Chen K
    Cancer Immunol Res; 2021 Jul; 9(7):838-852. PubMed ID: 34011528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of TGF-β responsiveness in prostate stromal cells alters chemokine levels and facilitates the development of mixed osteoblastic/osteolytic bone lesions.
    Li X; Sterling JA; Fan KH; Vessella RL; Shyr Y; Hayward SW; Matrisian LM; Bhowmick NA
    Mol Cancer Res; 2012 Apr; 10(4):494-503. PubMed ID: 22290877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Dormancy Mechanism of Castration Resistance in Bone Metastatic Prostate Cancer Organoids.
    Lee S; Mendoza TR; Burner DN; Muldong MT; Wu CCN; Arreola-Villanueva C; Zuniga A; Greenburg O; Zhu WY; Murtadha J; Koutouan E; Pineda N; Pham H; Kang SG; Kim HT; Pineda G; Lennon KM; Cacalano NA; Jamieson CHM; Kane CJ; Kulidjian AA; Gaasterland T; Jamieson CAM
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzalutamide-induced Proteolytic Degradation of the Androgen Receptor in Prostate Cancer Cells Is Mediated Only to a Limited Extent by the Proteasome System.
    Erb HHH; Oster MA; Gelbrich N; Cammann C; Thomas C; Mustea A; Stope MB
    Anticancer Res; 2021 Jul; 41(7):3271-3279. PubMed ID: 34230121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mifepristone Has Limited Activity to Enhance the
    Yang Y; Li X; Mamouni K; Kucuk O; Wu D
    Anticancer Res; 2017 Nov; 37(11):6235-6243. PubMed ID: 29061806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer.
    Armstrong CM; Liu C; Liu L; Yang JC; Lou W; Zhao R; Ning S; Lombard AP; Zhao J; D'Abronzo LS; Evans CP; Li PK; Gao AC
    Clin Cancer Res; 2020 Nov; 26(22):6064-6074. PubMed ID: 32928794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic Reprogramming and Predominance of Solute Carrier Genes during Acquired Enzalutamide Resistance in Prostate Cancer.
    Verma S; Shankar E; Chan ER; Gupta S
    Cells; 2020 Nov; 9(12):. PubMed ID: 33255236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity.
    Monga J; Adrianto I; Rogers C; Gadgeel S; Chitale D; Alumkal JJ; Beltran H; Zoubeidi A; Ghosh J
    J Biol Chem; 2022 Feb; 298(2):101556. PubMed ID: 34973338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones.
    Leung JK; Tam T; Wang J; Sadar MD
    Hum Cell; 2021 Jan; 34(1):211-218. PubMed ID: 32954481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer.
    Farah E; Zhang Z; Utturkar SM; Liu J; Ratliff TL; Liu X
    Mol Cancer Ther; 2022 Jan; 21(1):193-205. PubMed ID: 34728570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
    Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
    Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Syntaxin 6-mediated exosome secretion regulates enzalutamide resistance in prostate cancer.
    Peak TC; Panigrahi GK; Praharaj PP; Su Y; Shi L; Chyr J; Rivera-Chávez J; Flores-Bocanegra L; Singh R; Vander Griend DJ; Oberlies NH; Kerr BA; Hemal A; Bitting RL; Deep G
    Mol Carcinog; 2020 Jan; 59(1):62-72. PubMed ID: 31674708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-apoptotic function of caspase-8 confers prostate cancer enzalutamide resistance via NF-κB activation.
    Xia J; Zhang J; Wang L; Liu H; Wang J; Liu J; Liu Z; Zhu Y; Xu Y; Yang W; Yu Y
    Cell Death Dis; 2021 Sep; 12(9):833. PubMed ID: 34482382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lycopene enhances the sensitivity of castration-resistant prostate cancer to enzalutamide through the AKT/EZH2/ androgen receptor signaling pathway.
    Chen X; Yang G; Liu M; Quan Z; Wang L; Luo C; Wu X; Zheng Y
    Biochem Biophys Res Commun; 2022 Jul; 613():53-60. PubMed ID: 35533600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer.
    Gao L; Zhang W; Zhang J; Liu J; Sun F; Liu H; Hu J; Wang X; Wang X; Su P; Chen S; Qu S; Shi B; Xiong X; Chen W; Dong X; Han B
    Cancer Res; 2021 Feb; 81(4):1026-1039. PubMed ID: 33277366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.